U.S. FDA Warning Poses Threat to Dr. Reddy's Revenue Outlook

Dr. Reddy’s Laboratories Ltd., India’s second-largest drugmaker, could see its sales come under pressure as it faces scrutiny from the U.S. Food and Drug Administration over manufacturing practices at its factories. The generic drugmaker plunged 15 percent in early November after it received a warning letter from the FDA over potential violations at three facilities. The stock accelerated its declines yesterday after the U.S. agency posted the letter online, detailing problems with quality control and...